Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Takeda Considering Manufacturing Plant Move on Power Shortage: Keizai Doyukai Chairman Hasegawa
April 5, 2012
- Nihon Chouzai to Soon Conclude Memorandum with Wholesalers for Provisional Prices
April 5, 2012
- Pharmacists Expect Increase in Use of Amlodipine Generics: Survey
April 5, 2012
- GSK Applies for Fixed-Dose Combination Tablet for Treatment/Prevention of Malaria
April 5, 2012
- Shionogi Sees Positive Results of PIII Study for Anti-HIV Drug
April 5, 2012
- Ajinomoto Pharmaceuticals Obtains Rights to Develop, Commercialize CC Treatment in Japan, Asia
April 5, 2012
- Ajinomoto Pharmaceuticals Ties Up with DKSH Group in Vietnam
April 5, 2012
- Novartis Draws Up Guidelines for MRs on How to Cope in Times of Disaster
April 4, 2012
- Sogo Rinsho HD to Establish New Subsidiary for Full-Scale Market Entry of CRO Business
April 4, 2012
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
- Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
- Top Leaders Stress Importance of Globalization in Addresses to Incoming New Graduates
April 4, 2012
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
- Shionogi Acquires Global Rights for OncoTheraphy’s Cancer Vaccines
April 2, 2012
- Kyowa Kirin’s Expected Mainstay POTELIGEO Approved
April 2, 2012
- GSK, DSP Begin Copromotion of Paxil CR Tablets from April
April 2, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…